Advances in genomics and personalized medicine are likely to drive the future of drug repositioning. By understanding the genetic and molecular basis of different cancers, researchers can better identify existing drugs that might be effective. Collaborative efforts between academia, industry, and regulatory bodies will also be crucial in overcoming the challenges associated with drug repositioning.
